InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the Committee for Medicinal Products for Human ...
The following is a summary of “Predictive Factors in Asymptomatic Bacteriuria Treatment: Results From a Single-Center Rural Veterans Hospital ,” published in the November 2024 issue of Infectious ...